Safety and Efficacy of Favipiravir in Moderate to Severe SARS-CoV-2 Pneumonia

Methods: We did a multicenter randomized open-labeled clinical trial on moderate to severe cases infections of SARS-CoV-2. Patients with typical ground glass appearance on chest computerized tomography scan (CT scan) and oxygen saturation (SpO) of less than 93% were enrolled. They were randomly allocated into Favipiravir (1.6 gr loading, 1.8 gr daily) and Lopinavir/Ritonavir (800/200 mg daily) treatment regimens in addition to standard care. In-hospital mortality, ICU admission, intubation, time to clinical recovery, changes in daily SpO after 5 min discontinuation of supplemental oxygen, and length of hospital stay were quantified and compared in the two groups.

Results: 380 patients were randomly allocated into Favipiravir (193) and Lopinavir/Ritonavir (187) groups in 13 centers. The number of deaths, intubations, and ICU admissions were not significantly different (26, 27, 31 and 21, 17, 25 respectively). Mean hospital stay was also not different (7.9 days [SD = 6] in the Favipiravir and 8.1 [SD = 6.5] days in Lopinavir/Ritonavir groups) (p = 0.61). Time to clinical recovery in the Favipiravir group was similar to Lopinavir/Ritonavir group (HR = 0.94, 95% CI 0.75 - 1.17) and likewise the changes in the daily SpO after discontinuation of supplemental oxygen (p = 0.46) CONCLUSION: Adding Favipiravir to the treatment protocol did not reduce the number of ICU admissions or intubations or In-hospital mortality compared to Lopinavir/Ritonavir regimen. It also did not shorten time to clinical recovery and length of hospital stay.

Citing Articles

Favipiravir pharmacokinetics in Thai adults with mild COVID-19: A sub-study of interpatient variability and ethnic differences in exposure.

Prasanchaimontri I, Manosuthi W, Pertinez H, Owen A, Niyomnaitham S, Sirijatuphat R Pharmacol Res Perspect. 2024; 12(6):e1233.

PMID: 39509583 PMC: 11542727. DOI: 10.1002/prp2.1233.

Clinical Course and Factors Associated With Hospital Admission and Mortality among Sars-Cov 2 Patients within Nairobi Metropolitan Area.

Njuguna A, Wangombe A, Walekhwa M, Kamondo D medRxiv. 2024; .

PMID: 38798388 PMC: 11118643. DOI: 10.1101/2024.05.15.24307403.

Evaluation of the relationship of treatment and vaccination with prognosis in patients with a diagnosis of COVID-19.

Oncu S, Korkmaz D Inflammopharmacology. 2024; 32(3):1817-1826.

PMID: 38493271 PMC: 11136715. DOI: 10.1007/s10787-024-01457-4.

Favipiravir for treating COVID-19.

Korula P, Alexander H, John J, Kirubakaran R, Singh B, Tharyan P Cochrane Database Syst Rev. 2024; 2:CD015219.

PMID: 38314855 PMC: 10840071. DOI: 10.1002/14651858.CD015219.pub2.

Clinical antiviral efficacy of favipiravir in early COVID-19 (PLATCOV): an open-label, randomised, controlled, adaptive platform trial.

Luvira V, Schilling W, Jittamala P, Watson J, Boyd S, Siripoon T BMC Infect Dis. 2024; 24(1):89.

PMID: 38225598 PMC: 10789040. DOI: 10.1186/s12879-023-08835-3.

References

Tuccori M, Convertino I, Ferraro S, Cappello E, Valdiserra G, Focosi D . The Impact of the COVID-19 "Infodemic" on Drug-Utilization Behaviors: Implications for Pharmacovigilance. Drug Saf. 2020; 43(8):699-709. PMC: 7307939. DOI: 10.1007/s40264-020-00965-w. View

Meini S, Pagotto A, Longo B, Vendramin I, Pecori D, Tascini C . Role of Lopinavir/Ritonavir in the Treatment of Covid-19: A Review of Current Evidence, Guideline Recommendations, and Perspectives. J Clin Med. 2020; 9(7). PMC: 7408758. DOI: 10.3390/jcm9072050. View

Fu D, Cao R, Zhao L, Li W, Zhong W, Wen J . Oral favipiravir for patients with delayed SARS-CoV-2 viral RNA clearance: a case series. Crit Care. 2020; 24(1):578. PMC: 7517732. DOI: 10.1186/s13054-020-03288-5. View

McCullough P . Favipiravir and the Need for Early Ambulatory Treatment of SARS-CoV-2 Infection (COVID-19). Antimicrob Agents Chemother. 2020; 64(12). PMC: 7674042. DOI: 10.1128/AAC.02017-20. View

Mason R . Pathogenesis of COVID-19 from a cell biology perspective. Eur Respir J. 2020; 55(4). PMC: 7144260. DOI: 10.1183/13993003.00607-2020. View

Moschini L, Loffi M, Regazzoni V, Di Tano G, Gherbesi E, Danzi G . Effects on QT interval of hydroxychloroquine associated with ritonavir/darunavir or azithromycin in patients with SARS-CoV-2 infection. Heart Vessels. 2020; 36(1):115-120. PMC: 7364290. DOI: 10.1007/s00380-020-01671-4. View

Catanzaro M, Fagiani F, Racchi M, Corsini E, Govoni S, Lanni C . Immune response in COVID-19: addressing a pharmacological challenge by targeting pathways triggered by SARS-CoV-2. Signal Transduct Target Ther. 2020; 5(1):84. PMC: 7255975. DOI: 10.1038/s41392-020-0191-1. View

Sissoko D, Laouenan C, Folkesson E, MLebing A, Beavogui A, Baize S . Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea. PLoS Med. 2016; 13(3):e1001967. PMC: 4773183. DOI: 10.1371/journal.pmed.1001967. View

Jin Y, Cai L, Cheng Z, Cheng H, Deng T, Fan Y . A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version). Mil Med Res. 2020; 7(1):4. PMC: 7003341. DOI: 10.1186/s40779-020-0233-6. View

10.

Geleris J, Sun Y, Platt J, Zucker J, Baldwin M, Hripcsak G . Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19. N Engl J Med. 2020; 382(25):2411-2418. PMC: 7224609. DOI: 10.1056/NEJMoa2012410. View

11.

Sanders J, Monogue M, Jodlowski T, Cutrell J . Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review. JAMA. 2020; 323(18):1824-1836. DOI: 10.1001/jama.2020.6019. View

12.

Kivrak A, Ulas B, Kivrak H . A comparative analysis for anti-viral drugs: Their efficiency against SARS-CoV-2. Int Immunopharmacol. 2020; 90:107232. PMC: 7703546. DOI: 10.1016/j.intimp.2020.107232. View

13.

Tang W, Cao Z, Han M, Wang Z, Chen J, Sun W . Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. BMJ. 2020; 369:m1849. PMC: 7221473. DOI: 10.1136/bmj.m1849. View

14.

Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G . A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med. 2020; 382(19):1787-1799. PMC: 7121492. DOI: 10.1056/NEJMoa2001282. View

15.

Vijayvargiya P, Esquer Garrigos Z, Castillo Almeida N, Gurram P, Stevens R, Razonable R . Treatment Considerations for COVID-19: A Critical Review of the Evidence (or Lack Thereof). Mayo Clin Proc. 2020; 95(7):1454-1466. PMC: 7190528. DOI: 10.1016/j.mayocp.2020.04.027. View

16.

Du Y, Chen X . Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2019-nCoV Infection. Clin Pharmacol Ther. 2020; 108(2):242-247. DOI: 10.1002/cpt.1844. View

17.

Giammaria D, Pajewski A . Can early treatment of patients with risk factors contribute to managing the COVID-19 pandemic?. J Glob Health. 2020; 10(1):010377. PMC: 7307801. DOI: 10.7189/jogh.10.010377. View

18.

Cai Q, Yang M, Liu D, Chen J, Shu D, Xia J . Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study. Engineering (Beijing). 2020; 6(10):1192-1198. PMC: 7185795. DOI: 10.1016/j.eng.2020.03.007. View

19.

Dabbous H, Abd-Elsalam S, El-Sayed M, Sherief A, Ebeid F, Abd El Ghafar M . Efficacy of favipiravir in COVID-19 treatment: a multi-center randomized study. Arch Virol. 2021; 166(3):949-954. PMC: 7829645. DOI: 10.1007/s00705-021-04956-9. View

20.

Wu J, Li W, Shi X, Chen Z, Jiang B, Liu J . Early antiviral treatment contributes to alleviate the severity and improve the prognosis of patients with novel coronavirus disease (COVID-19). J Intern Med. 2020; 288(1):128-138. DOI: 10.1111/joim.13063. View